Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Metadata
Title
99mTc-EC-deoxyglucose—a poor man’s 18F-FDG: what will be the future of PET in molecular imaging?
Author
Maseeh uz Zaman
Publication date
01-03-2007
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2007
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-006-0299-8

Other articles of this Issue 3/2007

European Journal of Nuclear Medicine and Molecular Imaging 3/2007 Go to the issue

Book review

Henry N. Wagner Jr: A personal history of nuclear medicine. Springer Verlag, Berlin Heidelberg New York, 2006. ISBN 10: 1-85233-972-1

Original article

FDG PET as a predictor of response to resynchronisation therapy in patients with ischaemic cardiomyopathy

Original article

123I-labeled HIV-1 tat peptide radioimmunoconjugates are imported into the nucleus of human breast cancer cells and functionally interact in vitro and in vivo with the cyclin-dependent kinase inhibitor, p21WAF-1/Cip-1

Original article

Evaluation of iterative reconstruction (OSEM) versus filtered back-projection for the assessment of myocardial glucose uptake and myocardial perfusion using dynamic PET

Editorial commentary

Selection of heart failure patients for cardiac resynchronisation therapy: a role for PET?

Letter to the Editor

FDG-PET in the clinical management of carcinoma of unknown primary with metastatic cervical lymphadenopathy: shifting gears from detecting the primary to planning therapeutic strategies